Teva Pharmaceutical Industries confirmed it is to start Phase III studies with TEV-48125, its humanized monoclonal antibody against calcitonin-gene-related peptide (CGRP), but the company was not giving details on timings and indications as it published online Sept. 30 the full Phase IIb clinical trial results with the product in episodic migraine and chronic migraine, in two papers in The Lancet Neurology.
Adding to top-line data from Phase IIb studies announced at leading international headache conferences this year, the two scientific papers...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
